Succipro
1 known investors
Succipro is a biotech spin-off from IRB CatSud and Universitat Rovira i Virgili developing first-in-class drugs that modulate succinate to treat inflammatory bowel disease and metabolic disorders. Its lead program targets inflammatory bowel disease, with additional planned indications in metabolic conditions such as metabolic dysfunction-associated fatty liver.
Investors Β· 1
Frequently asked questions
- What does Succipro do?
- Succipro is a biotech spin-off from IRB CatSud and Universitat Rovira i Virgili developing first-in-class drugs that modulate succinate to treat inflammatory bowel disease and metabolic disorders. Its lead program targets inflammatory bowel disease, with additional planned indications in metabolic conditions such as metabolic dysfunction-associated fatty liver.
- Who are Succipro's investors?
- Succipro's investors include WA4STEAM.